Lilit Karapetyan, MD, MS, FACP

Lilit Karapetyan, MD, MS, discusses the importance of considering TIL therapy for melanoma in advance and not as a last resort.

Lilit Karapetyan, MD, MS, discusses how a single-center trial suggests patients with poorer performance status could be eligible for tumor-infiltrating lymphocyte therapy.

Lilit Karapetyan, MD, MS, discusses a single-center trial of reduced-intensity conditioning before tumor-infiltrating lymphocyte therapy in melanoma.

Results of a single-center study showed positive outcomes of reduced-intensity conditioning for tumor-infiltrating lymphocytes in melanoma.